Medicare Enrolled
Farah Nasraty
Internal Medicine · La Jolla, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Nasraty from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Nasraty?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Nasraty
Farah Nasraty is an internal medicine specialist in La Jolla, CA, with 12 years of NPI registration. Based on federal Medicare data, Nasraty performed 65,202 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Nasraty received a total of $8,450 from 64 pharmaceutical and/or device companies across 360 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Nasraty is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years of NPI registration
▲ Top 0% volume in CA
$8,450 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗65,202
Medicare services
Top 0% in CA for internal medicine
Not available
Unique patients (not deduplicated)
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 14,163 | $18 | $73 |
| Anti-nausea injection (aprepitant) | 11,310 | $1 | $7 |
| Paclitaxel chemotherapy injection | 10,572 | $0 | $1 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
9,900 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 5,800 | $42 | $170 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,206 | $0 | $1 |
| Trastuzumab biosimilar injection, 10 mg An injection of trastuzumab-qyyp, a biosimilar medication, administered in a 10 mg dose. |
1,983 | $17 | $211 |
| Injection, granisetron hydrochloride, 100 mcg | 1,900 | $0 | $3 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,700 | $23 | $207 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
924 | $77 | $1,806 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
683 | $13 | $55 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
586 | $97 | $350 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
436 | $116 | $479 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
407 | $2 | $15 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
338 | $12 | $46 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
321 | $142 | $491 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
226 | $6 | $38 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
215 | $55 | $236 |
| Injection, potassium chloride, per 2 meq | 175 | $0 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
156 | $57 | $232 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
104 | $24 | $100 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
102 | $22 | $94 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
96 | $30 | $114 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
96 | $105 | $1,390 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
93 | $23 | $110 |
| New patient office visit, complex (60-74 min) | 77 | $170 | $598 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
73 | $1 | $6 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
71 | $16 | $65 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
68 | $2 | $10 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
67 | $11 | $44 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
63 | $18 | $72 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
61 | $25 | $104 |
| Blood or blood product transfusion The administration of whole blood or specific blood components into a patient's bloodstream. |
45 | $35 | $157 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
36 | $17 | $70 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
34 | $1 | $10 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
26 | $29 | $118 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
23 | $87 | $359 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
19 | $8 | $14 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $59 | $248 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
14 | $63 | $187 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
14 | $1 | $41 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.7% high complexity
96.1% medium
2.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,450
Total received (2018-2024)
Avg $1,207/year across 7 years
Top 11% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
64
Companies
360
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,330
2023
$1,355
2022
$1,078
2021
$554
2020
$1,281
2019
$1,827
2018
$1,026
Payments by company (2024)
Alexion Pharmaceuticals, Inc.
$236
Daiichi Sankyo Inc.
$209
PFIZER INC.
$165
BeiGene USA, Inc.
$105
Incyte Corporation
$81
Lilly USA, LLC
$71
TAIHO ONCOLOGY, INC.
$64
Gilead Sciences, Inc.
$47
Merck Sharp & Dohme LLC
$43
Eisai Inc.
$43
SOBI, INC
$41
TerSera Therapeutics LLC
$34
Rigel Pharmaceuticals, Inc.
$34
Takeda Pharmaceuticals U.S.A., Inc.
$33
Novartis Pharmaceuticals Corporation
$29
ABBVIE INC.
$27
Deciphera Pharmaceuticals Inc.
$26
SpringWorks Therapeutics, Inc.
$25
Kite Pharma, Inc.
$17
Top 3 companies account for 45.8% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$681
AstraZeneca Pharmaceuticals LP
$583
Daiichi Sankyo Inc.
$561
Alexion Pharmaceuticals, Inc.
$550
PFIZER INC.
$545
Merck Sharp & Dohme Corporation
$409
Incyte Corporation
$381
Gilead Sciences, Inc.
$340
Pharmacyclics LLC, An AbbVie Company
$284
Takeda Pharmaceuticals U.S.A., Inc.
$270
Novartis Pharmaceuticals Corporation
$214
Celgene Corporation
$211
Seagen Inc.
$188
Rigel Pharmaceuticals, Inc.
$183
BeiGene USA, Inc.
$177
Lilly USA, LLC
$165
Puma Biotechnology, Inc.
$157
SOBI, INC
$139
Karyopharm Therapeutics Inc.
$138
Eisai Inc.
$128
Aurobindo Pharma USA, Inc.
$125
Genentech USA, Inc.
$125
E.R. Squibb & Sons, L.L.C.
$124
ABBVIE INC.
$116
Merck Sharp & Dohme LLC
$113
GlaxoSmithKline, LLC.
$110
Foundation Medicine, Inc.
$109
AbbVie, Inc.
$82
Janssen Biotech, Inc.
$72
Sobi, Inc
$67
Clovis Oncology, Inc.
$67
TerSera Therapeutics LLC
$65
TAIHO ONCOLOGY, INC.
$64
EMD Serono, Inc.
$63
Exelixis Inc.
$59
Seattle Genetics, Inc.
$53
GENZYME CORPORATION
$48
Blueprint Medicines Corporation
$44
Kite Pharma, Inc.
$44
Astellas Pharma US Inc
$38
Spectrum Pharmaceuticals Inc.
$37
AVEO Pharmaceuticals, Inc.
$36
Boehringer Ingelheim Pharmaceuticals, Inc.
$36
Pharmacyclics LLC, an AbbVie Company
$33
Regeneron Healthcare Solutions, Inc.
$33
TESARO, Inc.
$32
EISAI INC.
$31
ARRAY BIOPHARMA INC
$27
Deciphera Pharmaceuticals Inc.
$26
SpringWorks Therapeutics, Inc.
$25
Epizyme, Inc.,
$22
Agios Pharmaceuticals, Inc.
$22
PUMA BIOTECHNOLOGY, INC.
$21
Acceleron Pharma, Inc.
$20
Ipsen Biopharmaceuticals, Inc
$19
Bayer HealthCare Pharmaceuticals Inc.
$19
Mirati Therapeutics, Inc.
$19
MorphoSys, US Inc.
$18
Heron Therapeutics, Inc.
$16
Genmab U.S., Inc.
$16
Alnylam Pharmaceuticals Inc.
$16
Otsuka America Pharmaceutical, Inc.
$15
Janssen Pharmaceuticals, Inc
$14
Secura Bio, Inc.
$7
Top 3 companies account for 21.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Abraxane · Aliqopa · Avastin · BLENREP · BRAFTOVI · BRUKINSA · Blincyto · CALQUENCE · CINVANTI · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ENHERTU · Enhertu · Epkinly · FOTIVDA · FOUNDATIONONE · Farydak · Folotyn · GAVRETO · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · Imbruvica · Inrebic · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · Lenvima · MONJUVI · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OGSIVEO · ONPATTRO · OPDIVO · PIQRAY · PREVYMIS · PROMACTA · PYRUKYND · Pomalyst · QINLOCK · Reblozyl · Revlimid · Rezlidhia · Rubraca · SARCLISA · SPRYCEL · Somatuline Depot · TAGRISSO · TAZVERIK · TECENTRIQ · TUKYSA · Tavalisse · Trodelvy · Turalio · ULTOMIRIS · Ultomiris · VARUBI · VELCADE · VENCLEXTA · VERZENIO · Vanflyta · Vectibix · Venclexta · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · YERVOY · Yescarta · ZEJULA · ZOLADEX · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
1,707
County median income
$102,285
Nearest hospital to ZIP centroid (approximate)
SCRIPPS MEMORIAL HOSPITAL LA JOLLA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Nasraty is a mixed practice specialist, with above-average Medicare volume (top 0% in CA).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Nasraty experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Nasraty performed 14,163 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Nasraty receive payments from pharmaceutical companies?
Yes. Nasraty received a total of $8,450 from 64 companies across 360 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Nasraty's costs compare to other internal medicine physicians in La Jolla?
Nasraty's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Nasraty) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in La Jolla
Browse internal medicine physicians in La Jolla ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology